4.5 Article

Proteinuria reduction with SGLT2 inhibitors in a patient treated with tyrosine kinase inhibitor lenvatinib

期刊

JOURNAL OF NEPHROLOGY
卷 -, 期 -, 页码 -

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s40620-023-01701-0

关键词

Proteinuria; Tyrosine kinase inhibitors; SGLT2 inhibitors; Lenvatinib

向作者/读者索取更多资源

We present a case of a 66-year-old woman with thyroid carcinoma who had persistent proteinuria despite maximal angiotensin-converting enzyme inhibitor dose. Treatment with SGLT2 inhibitor Dapagliflozin resulted in a significant reduction in proteinuria after 3 months. This is the first reported case of successful proteinuria reduction with SGLT2i in a patient treated with tyrosine kinase inhibitor.
We describe the case of a 66-year-old woman treated with tyrosine kinase inhibitor Lenvatinib for thyroid carcinoma who had persistent proteinuria above 2 g/24 h despite maximal dose of angiotensin-converting enzyme inhibitor. We initiated a treatment with SGLT2 inhibitor Dapagliflozin. Three months after Dapagliflozin initiation, her proteinuria decreased to 1 g/24 h, and after 6 months of follow-up was 0.6 g/24 h. To our knowledge, this is the first case of successful proteinuria reduction with SGLT2i in a patient treated with Lenvatinib. Specific renal effects of SGLT2i seem promising and their effects on tyrosine kinase inhibitor renal adverse effects need to be validated in clinical trials involving cancer patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据